August 6, 2024 01:21 PM EDTUpdated August 7, 08:57 AM
Pharma
Law

No­vo Nordisk goes af­ter more com­pounders, ex­pand­ing GLP-1 law­suit cam­paign

Nicole DeFeudis

Editor

No­vo Nordisk is turn­ing up the heat on com­pound­ing phar­ma­cies mak­ing ver­sions of its block­buster.

Late last week, the com­pa­ny filed 11 new law­suits against …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times